82_FR_10808 82 FR 10778 - Government-Owned Inventions; Availability for Licensing

82 FR 10778 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 30 (February 15, 2017)

Page Range10778-10779
FR Document2017-03017

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 30 (Wednesday, February 15, 2017) 
[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10778-10779]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03017]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for

[[Page 10779]]

licensing to achieve expeditious commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Synergistic Internal Ribosomal Entry Site (IRES)--MicroRNA-Based 
Approach for Attenuation of Flaviviruses and Live Vaccine Development

    Description of Technology: Many members of the Flaviviridae family 
are emerging and reemerging human pathogens that have caused outbreaks 
of devastating and often fatal diseases and represent a serious public 
health problem on a global scale. There is no single attenuation 
strategy that exists which is sufficient to prepare a safe, efficacious 
and immunogenic live attenuated virus vaccine that will work 
universally for Flaviviridae. This patent application claims live 
attenuated flavivirus vaccines, live attenuated multivalent flavivirus 
vaccines, and methods of preventing flavivirus infections as well as 
methods of making the vaccines claimed in the application. More 
specifically, this patent application claims methods for attenuating a 
flavivirus or chimeric flavivirus using a synergistic dual strategy 
involving inserting miRNA-targeting sequences to restrict virus 
replication in target hosts, cells and/or tissues and placing one or 
more flavivirus genes under translational control of an internal 
ribosomal entry site (IRES).
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Diagnostics
 Vaccines

    Competitive Advantages:
 Potential one-dose flavivirus vaccine
 Ease of manufacture in Vero cells
 Low-cost potential vaccine
 Developing and developed world potential vaccines

    Development Stage:

 In vivo data available (animal)

    Inventors: Alexander Pletnev (NIAID), Konstantin Tsetsarkin 
(NIAID).
    Intellectual Property: HHS Reference No. E-006-2017/0--U.S. 
Provisional Application No. 62/443,214, filed January 6, 2017.
    Licensing Contact: Peter Soukas, J.D., 301-594-8730; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize vaccine(s) for prophylaxis against 
flavivirus infections. For collaboration opportunities, please contact 
Peter Soukas, J.D., 301-594-8730; [email protected].

    Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03017 Filed 2-14-17; 8:45 am]
 BILLING CODE 4140-01-P

10778 Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices Committee shall be made without published in the Federal Register on DEPARTMENT OF HEALTH AND discrimination on the basis of age, race, January 23, 2017, 82 FR 7842. HUMAN SERVICES ethnicity, gender, sexual orientation, The meeting will be held on 02/17/ disability, and cultural, religious, or National Institutes of Health 2017 instead of 02/16/2017–02/17/2017. socioeconomic status. Requests for The meeting time and location remains reasonable accommodation to enable National Institute of Allergy and the same. The meeting is closed to the Infectious Diseases; Notice of Closed participation on the Committee should public. Meeting be indicated in the nomination submission. Dated: February 9, 2017. Pursuant to section 10(d) of the Member Terms: Non-Federal public David Clary, Federal Advisory Committee Act, as members of the Committee serve for a Program Analyst, Office of Federal Advisory amended (5 U.S.C. App.), notice is term of 3 years, and may serve for an Committee Policy. hereby given of the following meeting. unlimited number of terms if [FR Doc. 2017–03013 Filed 2–14–17; 8:45 am] The meeting will be closed to the reappointed. Members may serve after BILLING CODE 4140–01–P public in accordance with the the expiration of their terms, until their provisions set forth in sections successors have taken office. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Meetings and Travel: As specified by DEPARTMENT OF HEALTH AND as amended. The grant applications and Pub. L. 113–166, the MDCC ‘‘shall meet HUMAN SERVICES the discussions could disclose no fewer than two times per calendar confidential trade secrets or commercial year.’’ Travel expenses are provided for National Institutes of Health property such as patentable material, non-federal public Committee members and personal information concerning to facilitate attendance at in-person National Institute of Biomedical individuals associated with the grant meetings. Members are expected to Imaging and Bioengineering; Notice of applications, the disclosure of which make every effort to attend all full Closed Meeting would constitute a clearly unwarranted committee meetings, twice per year, invasion of personal privacy. either in person or via remote access. Pursuant to section 10(d) of the Name of Committee: Microbiology, Participation in relevant subcommittee, Federal Advisory Committee Act, as Infectious Diseases and AIDS Initial Review working and planning group meetings, amended (5 U.S.C. App.), notice is Group; Microbiology and Infectious Diseases and workshops, is also encouraged. hereby given of the following meeting. B Subcommittee MID–B March 2017. Date: March 6–7, 2017. Submission Instructions and The meeting will be closed to the Time: 8:00 a.m. to 5:00 p.m. Deadline: Nominations are due by 5 public in accordance with the Agenda: To review and evaluate grant p.m. EST on March 17, 2017, and provisions set forth in sections applications. should be sent to Glen Nuckolls, Ph.D., 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: Marriott Courtyard Gaithersburg by email to nuckollg@ninds.nih.gov. Washingtonian Center, 204 Boardwalk Place, as amended. The grant applications and Gaithersburg, MD 20878. Nominations must include contact the discussions could disclose information for the nominee, a current Contact Person: Ellen S. Buczko, Ph.D., confidential trade secrets or commercial Scientific Review Officer, Scientific Review curriculum vitae or resume of the Program, Division of Extramural Activities, property such as patentable material, nominee and a paragraph describing the National Institutes of Health/NIAID, 6700B and personal information concerning qualifications of the person to represent Rockledge Drive, MSC 7616, Bethesda, MD some portion(s) of the muscular individuals associated with the grant 20892–7616, 301–451–2676, ebuczko1@ dystrophy research, advocacy and/or applications, the disclosure of which niaid.nih.gov. patient care communities. would constitute a clearly unwarranted (Catalogue of Federal Domestic Assistance More information about the MDCC is invasion of personal privacy. Program Nos. 93.855, Allergy, Immunology, available at https://mdcc.nih.gov/. Name of Committee: National Institute of and Transplantation Research; 93.856, Microbiology and Infectious Diseases Dated: February 10, 2017. Biomedical Imaging and Bioengineering Research, National Institutes of Health, HHS) Special Emphasis Panel; K Award—R13 Walter J. Koroshetz, Dated: February 9, 2017. Review Meeting (2017/05). Director, National Institute of Neurological Date: March 9, 2017. Natasha M. Copeland, Disorders and Stroke, National Institutes of Time: 10:00 a.m. to 6:00 p.m. Program Analyst, Office of Federal Advisory Health. Agenda: To review and evaluate grant Committee Policy. [FR Doc. 2017–03018 Filed 2–14–17; 8:45 am] applications. [FR Doc. 2017–03014 Filed 2–14–17; 8:45 am] BILLING CODE 4140–01–P Place: National Institutes of Health, Two BILLING CODE 4140–01–P Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual DEPARTMENT OF HEALTH AND Meeting). DEPARTMENT OF HEALTH AND HUMAN SERVICES Contact Person: John K. Hayes, Ph.D., HUMAN SERVICES Scientific Review Officer, 6707 Democracy National Institutes of Health National Institutes of Health Boulevard, Suite 959, Democracy Two, Center for Scientific Review; Amended Bethesda, MD 20892, (301) 451–3398, hayesj@mail.nih.gov. Government-Owned Inventions; Notice of Meeting Availability for Licensing mstockstill on DSK3G9T082PROD with NOTICES Dated: February 9, 2017. Notice is hereby given of a change in AGENCY: National Institutes of Health, David Clary, the meeting of the Genetic Variation and HHS. Evolution Study Section, February 16, Program Analyst, Office of Federal Advisory Committee Policy. ACTION: Notice. 2017, 08:00 a.m. to February 17, 2017, 07:00 p.m., Renaissance M Street Hotel, [FR Doc. 2017–03012 Filed 2–14–17; 8:45 am] SUMMARY: The invention listed below is 1143 New Hampshire Avenue NW., BILLING CODE 4140–01–P owned by an agency of the U.S. Washington, DC 20037 which was Government and is available for VerDate Sep<11>2014 18:44 Feb 14, 2017 Jkt 241001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1

Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices 10779 licensing to achieve expeditious • Potential one-dose flavivirus vaccine 301–496–2644. A signed Confidential commercialization of results of • Ease of manufacture in Vero cells Disclosure Agreement will be required federally-funded research and • Low-cost potential vaccine to receive copies of unpublished patent development. Foreign patent • Developing and developed world applications. applications are filed on selected potential vaccines SUPPLEMENTARY INFORMATION: inventions to extend market coverage Development Stage: Technology description follows. for companies and may also be available • In vivo data available (animal) for licensing. A Bivalent Conjugate Vaccine for Inventors: Alexander Pletnev (NIAID), Malaria and Typhoid Prophylaxis FOR FURTHER INFORMATION CONTACT: Konstantin Tsetsarkin (NIAID). Licensing information and copies of the Intellectual Property: HHS Reference Description of Technology: Malaria is patent applications listed below may be No. E–006–2017/0—U.S. Provisional the single leading cause of mortality, obtained by communicating with the Application No. 62/443,214, filed especially among children in the indicated licensing contact at the January 6, 2017. developing world. Typhoid fever, Technology Transfer and Intellectual Licensing Contact: Peter Soukas, J.D., caused by infection with Salmonella Property Office, National Institute of 301–594–8730; peter.soukas@nih.gov. typhi, is known to be endemic with Allergy and Infectious Diseases, 5601 Collaborative Research Opportunity: malaria and causes its own significant Fishers Lane, Rockville, MD 20852; tel. The National Institute of Allergy and disease burden. Scientists at the 301–496–2644. A signed Confidential Infectious Diseases is seeking statements National Institute of Allergy and Disclosure Agreement will be required of capability or interest from parties Infectious Diseases (NIAID), part of the to receive copies of unpublished patent interested in collaborative research to National Institutes of Health, have applications. further develop, evaluate or developed a novel bivalent vaccine SUPPLEMENTARY INFORMATION: commercialize vaccine(s) for candidate that may effectively prevent Technology description follows. prophylaxis against flavivirus malaria and typhoid. This approach infections. For collaboration significantly enhances immune Synergistic Internal Ribosomal Entry opportunities, please contact Peter response to the Pfs25 Malaria Site (IRES)—MicroRNA-Based Soukas, J.D., 301–594–8730; transmission blocking antigen and Approach for Attenuation of peter.soukas@nih.gov. produces a robust immune response Flaviviruses and Live Vaccine against Salmonella typhi Vi Development Dated: February 6, 2017. polysaccharide (ViP). Description of Technology: Many Suzanne Frisbie, This technology is available for members of the Flaviviridae family are Deputy Director, Technology Transfer and licensing for commercial development emerging and reemerging human Intellectual Property Office, National Institute in accordance with 35 U.S.C. 209 and 37 pathogens that have caused outbreaks of of Allergy and Infectious Diseases. CFR part 404, as well as for further devastating and often fatal diseases and [FR Doc. 2017–03017 Filed 2–14–17; 8:45 am] development and evaluation under a represent a serious public health BILLING CODE 4140–01–P research collaboration. problem on a global scale. There is no Potential Commercial Applications: single attenuation strategy that exists DEPARTMENT OF HEALTH AND • Development of this technology which is sufficient to prepare a safe, HUMAN SERVICES into a vaccine may protect vulnerable efficacious and immunogenic live populations from both Malaria attenuated virus vaccine that will work National Institutes of Health transmission and Typhoid fever. universally for Flaviviridae. This patent application claims live attenuated Competitive Advantages: Government-Owned Inventions; • This technology has significant flavivirus vaccines, live attenuated Availability for Licensing multivalent flavivirus vaccines, and advantages over current treatments, methods of preventing flavivirus AGENCY: National Institutes of Health, since there is currently only one infections as well as methods of making HHS. commercial Malaria vaccine licensed for the vaccines claimed in the application. use in Europe only, which was not ACTION: Notice. More specifically, this patent developed to address Malaria application claims methods for SUMMARY: The invention listed below is transmission, and the currently licensed attenuating a flavivirus or chimeric owned by an agency of the U.S. Salmonella typhi vaccines show flavivirus using a synergistic dual Government and is available for incomplete efficacy and do not provide strategy involving inserting miRNA- licensing to achieve expeditious long-term immunity. A formulation of targeting sequences to restrict virus commercialization of results of the present technology has shown the replication in target hosts, cells and/or federally-funded research and ability to induce an immune response to tissues and placing one or more development. Foreign patent Pfs25 in excess of 100 times higher and flavivirus genes under translational applications are filed on selected Salmonella typhi antigen 20–40 times control of an internal ribosomal entry inventions to extend market coverage higher than what is seen by site (IRES). for companies and may also be available immunization with either antigen alone. This technology is available for for licensing. Development Stage: licensing for commercial development FOR FURTHER INFORMATION CONTACT: • In vivo data available (animal). in accordance with 35 U.S.C. 209 and 37 Licensing information and copies of the Inventors: Drs. Patrick Duffy, Sojung mstockstill on DSK3G9T082PROD with NOTICES CFR part 404, as well as for further patent applications listed below may be An, and Puthupparampil Scaria, NIAID, development and evaluation under a obtained by communicating with the NIH. research collaboration. indicated licensing contact at the Publications: None. Potential Commercial Applications: Technology Transfer and Intellectual Intellectual Property: Provisional • Diagnostics Property Office, National Institute of Patent application #62/327,184 Filed • Vaccines Allergy and Infectious Diseases, 5601 04/25/16, Technology reference #E– Competitive Advantages: Fishers Lane, Rockville, MD 20852; tel. 124–2016/0. VerDate Sep<11>2014 18:44 Feb 14, 2017 Jkt 241001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1


Document Created: 2017-02-15 00:55:14
Document Modified: 2017-02-15 00:55:14
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 10778 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR